Oppenheimer & Co. Inc. boosted its position in shares of Global Blood Therapeutics Inc (NASDAQ:GBT) by 30.3% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 15,897 shares of the company’s stock after purchasing an additional 3,700 shares during the period. Oppenheimer & Co. Inc.’s holdings in Global Blood Therapeutics were worth $604,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in GBT. Tiverton Asset Management LLC acquired a new stake in Global Blood Therapeutics during the 2nd quarter valued at $166,000. Quantitative Systematic Strategies LLC bought a new position in Global Blood Therapeutics during the 2nd quarter valued at $203,000. Great West Life Assurance Co. Can boosted its stake in Global Blood Therapeutics by 42.0% during the 2nd quarter. Great West Life Assurance Co. Can now owns 4,969 shares of the company’s stock valued at $224,000 after acquiring an additional 1,469 shares during the last quarter. Federated Investors Inc. PA bought a new position in Global Blood Therapeutics during the 2nd quarter valued at $226,000. Finally, Cambridge Investment Research Advisors Inc. bought a new position in Global Blood Therapeutics during the 2nd quarter valued at $240,000. 99.01% of the stock is owned by institutional investors and hedge funds.
In other news, insider Lesley Ann Calhoun sold 2,004 shares of the company’s stock in a transaction dated Friday, August 17th. The stock was sold at an average price of $49.89, for a total value of $99,979.56. Following the completion of the sale, the insider now directly owns 1,342 shares of the company’s stock, valued at approximately $66,952.38. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 4.40% of the company’s stock.
Global Blood Therapeutics (NASDAQ:GBT) last announced its quarterly earnings results on Tuesday, November 6th. The company reported ($0.83) EPS for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.02. During the same period in the prior year, the firm earned ($0.66) earnings per share. On average, research analysts anticipate that Global Blood Therapeutics Inc will post -3.38 earnings per share for the current year.
A number of research analysts have commented on the stock. ValuEngine upgraded shares of Global Blood Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Wednesday. William Blair reiterated a “buy” rating on shares of Global Blood Therapeutics in a research note on Wednesday. HC Wainwright set a $125.00 price objective on shares of Global Blood Therapeutics and gave the company a “buy” rating in a research note on Monday. BidaskClub upgraded shares of Global Blood Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Wednesday, August 8th. Finally, Cantor Fitzgerald set a $96.00 price objective on shares of Global Blood Therapeutics and gave the company a “buy” rating in a research note on Tuesday, October 23rd. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $80.20.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Dakota Financial News and is owned by of Dakota Financial News. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://dakotafinancialnews.com/2018/11/08/global-blood-therapeutics-inc-gbt-position-raised-by-oppenheimer-co-inc.html.
About Global Blood Therapeutics
Global Blood Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD.
Read More: 52-Week High/Low
Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.